PubMed: A Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating the Efficacy of Subcutaneous Hyperimmune Immunoglobulin Against COVID-19 in Asymptomatic Individuals with SARS-CoV-2 Infection for Disease Prevention.
Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic … Read more